Kelly A. Gebo, Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Sonya L. Heath, Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham , Birmingham, Alabama, USA.
Yuriko Fukuta, Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine , Houston, Texas, USA.
Xianming Zhu, Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Sheriza Baksh, Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Allison G. Abraham, Department of Epidemiology, University of Colorado, Anschutz Medical Campus , Aurora, Colorado, USA.
Feben Habtehyimer, Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
David Shade, Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Jessica Ruff, Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Malathi Ram, Departement of International Health, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Oliver Laeyendecker, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH , Baltimore, Maryland, USA.
Reinaldo E. Fernandez, Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Eshan U. Patel, Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Owen R. Baker, Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Shmuel Shoham, Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Edward R. Cachay, Department of Medicine, Division of Infectious Diseases, University of California , San Diego, California, USA.
Judith S. Currier, Department of Medicine, Division of Infectious Diseases, University of California , Los Angeles, California, USA.
Jonathan M. Gerber, Department of Medicine, Division of Hematology and Oncology, University of Massachusetts Chan Medical School , Worchester, Massachusetts, USA.
Barry Meisenberg, Luminis Health , Annapolis, Maryland, USA.
Donald N. Forthal, Department of Medicine, Division of Infectious Diseases, University of California , Irvine, California, USA.
Laura L. Hammitt, Departement of International Health, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Moises A. Huaman, Department of Medicine, Division of Infectious Diseases, University of Cincinnati , Cincinnati, Ohio, USA.
Adam Levine, Department of Emergency Medicine, Rhode Island Hospital Warren Alpert Medical School of Brown University , Providence, Rhode Island, USA.
Giselle S. Mosnaim, Department of Medicine, Division of Allergy and Immunology, Northshore University Health System , Evanston, Illinois, USA.
Bela Patel, Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center , Houston, Texas, USA.
James H. Paxton, Department of Emergency Medicine, Wayne State University , Detroit, Michigan, USA.
Jay S. Raval, Department of Pathology, University of New Mexico , Albuquerque, New Mexico, USA.
Catherine G. Sutcliffe, Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA. Department of Epidemiology, University of Colorado, Anschutz Medical Campus , Aurora, Colorado, USA.
Shweta Anjan, Department of Medicine, Division of Infectious Diseases, University of Miami, Miller School of Medicine , Miami, Florida, USA.
Thomas Gniadek, Department of Pathology, Northshore University Health System , Evanston, Illinois, USA.
Seble Kassaye, Division of Infectious Diseases, Medstar Georgetown University Hospital , Washington, DC, USA.
Janis E. Blair, Department of Medicine, Division of Infectious Diseases, Mayo Clinic Hospital , Phoenix, Arizona, USA.
Karen Lane, Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Nichol A. McBee, Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Amy L. Gawad, Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Piyali Das, Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Sabra L. Klein, Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Andrew Pekosz, Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Evan M. Bloch, Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Daniel Hanley, Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Arturo Casadevall, Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Aaron A R Tobian, Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
David J. Sullivan, Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.

Document Type

Article

Publication Date

10-31-2023

Abstract

Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.

Download

Share

COinS